Lead investigator of the PARALLAX trial discusses whether he feels clinical data related to sacubitril/valsartan is strong enough to warrant prescribing it for HFpEF patients.
Few agents have been as thoroughly studied for use in heart failure patients in recent years as sacubitril/valsartan (Entresto). In recent years, major clinical trials have examined the agent in HFrEF and, now, the PARALLAX trial is offering greater insight into the effects of sacubitril/valsartan in patients with heart failure with preserved ejection fraction (HFpEF).
Presented by Burkert Pieske, MD, professor of medicine and director of cardiology at Charite University Medicine, at the European Society of Cardiology (ESC) Congress 2020, results of the PARALLAX trial detail the benefit of sacubitril/valsartan on NT-proBNP levels in HFpEF patients. While the study failed to meet its other primary end point, data from the trial offer greater insight into the mechanisms and effects of the agent in patients with heart failure.
For more insight into the use of sacubitril/valsartan and whether the clinical trial data is sufficient enough to prescribe the agent to patients, Practical Cardiology reached out to Pieske to take part in a special ESC 2020 House Call.